VOLUNTARY ANNOUNCEMENT Announcement on the Progress of Share Repurchase
Filed with HKEX · Stock code 2595 · · 2 pages · English
GenFleet Therapeutics (Shanghai) Inc. 勁方醫藥科技(上海)股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2595) VOLUNTARY ANNOUNCEMENT ## Announcement on the Progress of Share Repurchase This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “Company” or “GenFleet”, together with its subsidiaries, the “Group”) on a voluntary
Genfleet Therapeutics (Shanghai), Inc. on 6ix
Earlier from Genfleet Therapeutics (Shanghai)
- 2026 Interim Report
- VOLUNTARY ANNOUNCEMENT Favorable Phase II Efficacy Data of GFH375 (Oral KRAS G12D Inhibitor) Monotherapy in Pretreated NSCLC Presented in Oral Session at 2026 World Conference on Lung Cancer (WCLC)
- Voluntary announcement proposed share repurchase on the market
Later from Genfleet Therapeutics (Shanghai)
- Announcement pursuant to rule 13.10 of the listing rules
- VOLUNTARY ANNOUNCEMENT Disclosure Arrangements for Clinical Data from Studies of GFH375 and GFH276
- Resignation of non-executive director
- List of directors and their roles and functions
- Next Day Disclosure Return
Follow Genfleet Therapeutics (Shanghai) into a list and get an email when it puts out news.
Follow Genfleet Therapeutics (Shanghai)